Chimeric antigen receptor‐T cell therapy shows similar efficacy and toxicity in patients with diffuse large B‐cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study

Abstract CD19‐directed chimeric antigen receptor (CAR)‐T cell therapy has become a standard treatment for relapsed/refractory diffuse large B‐cell lymphoma (r/r DLBCL). While the benefits of CAR‐T cell treatment are clear in the general patient population, there remains a relative scarcity of real‐w...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Philipp Berning, Evgenii Shumilov, Markus Maulhardt, Hristo Boyadzhiev, Andrea Kerkhoff, Simon Call, Christian Reicherts, Anna O. Saidy, Enver Aydilek, Michèle Hoffmann, Urban Novak, Michael Daskalakis, Norbert Schmitz, Matthias Stelljes, Gerald Wulf, Ulrike Bacher, Georg Lenz, Thomas Pabst
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Wiley 2024-03-01
Serie:	HemaSphere
Accesso online:	https://doi.org/10.1002/hem3.54
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!